Search the Newsreel

Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

Dimensional Fund Advisors LP significantly reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 55.9% in the first quarter, selling 10,801 shares and retaining 8,520 shares valued at approximately $4.46 million. Despite this reduction, institutional investors and hedge funds collectively own 98.5% of the company's …

Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com

Madrigal Pharmaceuticals Inc. filed a Form 8K on August 12. The article provides the title of the filing and mentions that it was published by Investing.com, along with the stock symbol MDGL and its current performance.

Madrigal Pharmaceuticals appoints J&J executive to board

Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, overseeing R&D across various therapeutic areas. Madrigal Pharmaceuticals is …

Madrigal's Board Adds Scientist With More Than 900 Papers

Madrigal Pharmaceuticals (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed, currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, brings extensive scientific, leadership, and global drug development experience. His expertise is …

Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada

Royal Bank of Canada increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 22.5% in the first quarter, bringing its holdings to 12,526 shares valued at approximately $6.6 million. Institutional investors collectively own 98.5% of the company, with other hedge funds also modifying their holdings. …

What Is Drawing Fresh Attention To Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals recently reported Q2 results showing increased net losses, drawing attention to its financial performance ahead of an upcoming investor conference. Despite recent volatility, the stock has shown strong long-term momentum with a 1-year total shareholder return of 47.45% and a 5-year return …

Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones

This article provides an analysis of Madrigal Pharmaceuticals Inc. (MDGL), highlighting a positive near-term sentiment within a long-term strong context, despite a weak mid-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The …

Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion

Madrigal Pharmaceuticals (MDGL) reported a wider net loss of US$57.94 million in Q2 2026, up from US$42.28 million a year earlier, driven by the costs of scaling its MASH-focused business. Despite the increased losses, the article emphasizes that the investment narrative hinges on Rezdiffra …

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals announced it granted equity inducement awards to ten new non-executive employees on August 1, 2026, under its 2025 Inducement Plan. These awards, totaling 4,263 time-based restricted stock units, were approved by the independent Compensation Committee according to Nasdaq Listing Rule 5635(c)(4). The …

Madrigal New Hires Get Stock Awards With Four-Year Vesting

Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity inducement awards totaling 4,263 time-based restricted stock units to ten new non-executive employees on August 1, 2026. These awards, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments over …

Madrigal’s Aug. 11 Investor Presentation Will Be Webcast Live

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced its participation in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company's presentation will be webcast live and accessible via Madrigal's Investor Relations Events and Presentations page, with a replay …

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals announced its participation in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 P.M. EDT. The company, focused on MASH therapeutics, will webcast its presentation live. Madrigal Pharmaceuticals is known for Rezdiffra, the first FDA and European …

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received an average "Moderate Buy" rating from analysts, with 15 out of 18 firms recommending a buy and an average 12-month price target of $689.93, significantly above its current trading price of approximately $514. The company recently surpassed quarterly expectations, …

Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach (NASDAQ:MDGL)

HC Wainwright Analysts Increase Earnings Estimates for MDGL

Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?

Madrigal Pharmaceuticals (MDGL) reported wider net losses in its second quarter, leading to a recent share price drop, though it still shows strong longer-term gains. Despite the wider losses, Simply Wall St's analysis suggests MDGL is undervalued, with a fair value of $678.71, largely …

Barclays lowers Madrigal Pharmaceuticals stock price target to $962

Barclays has lowered its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) stock to $962 from $964, while maintaining an Overweight rating. This decision comes despite recent stock weakness, which the firm views as a strong quarter. Madrigal Pharmaceuticals reported significant Q2 revenue growth, with Rezdiffra …

Madrigal Pharmaceuticals (MDGL) Stock Grapples With Widening Losses Despite Rezdiffra Growth

Madrigal Pharmaceuticals (MDGL) stock dropped 5.2% after reporting widening Q2 losses despite strong Rezdiffra sales and patient growth. The company's Q2 net sales reached US$364.3m, with over 49,000 active U.S. patients on Rezdiffra, but net losses increased to US$57.9m due to heavy investment in …

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?

Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals reported Q2 2026 results with widened net losses but stronger-than-expected sales of Rezdiffra and new patent protections extending into the 2040s for resmetirom. These developments reinforce the company's investment narrative, suggesting it can maintain its first-in-class position in MASH. While near-term sales …

Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar

Earnings call transcript: Madrigal Pharmaceuticals posts strong Q2 2026 sales, shares fall premarket

Madrigal Pharmaceuticals reported strong Q2 2026 net sales of $364.3 million for Rezdiffra, exceeding Wall Street forecasts, yet its shares declined due to a wider net loss and increased expenses. The company highlighted strong commercial execution, with active patients on Rezdiffra surpassing 49,000 and …

Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, vs. FactSet Est of $352.1M

Madrigal Pharmaceuticals, Inc. reported its Q2 revenue at $364.3 million, surpassing the FactSet estimate of $352.1 million. The company is focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and has its medication, Rezdiffra, approved for MASH with moderate to advanced fibrosis. Additionally, …

Madrigal: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Madrigal. Given the limited content, no further details about their financial performance are available.

Madrigal Begins Phase 1 Trial of Oral GLP-1 Drug for MASH

Madrigal Pharmaceuticals reported strong second-quarter 2026 net revenues of $364.3 million, a 71% increase year-over-year, driven by high demand for its MASH treatment, Rezdiffra, which now serves over 50,000 active patients. The company also announced

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals reported strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million and over 49,000 patients on the drug. The company strengthened its intellectual property with three new patents for resmetirom, advanced MGL-2086 (an oral GLP-1) into Phase 1 trials for …

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down - Time to Sell?

Madrigal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MDGL) 2026-07-30

Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Tri Locum Partners LP

MDGL Maintained by Canaccord Genuity -- Price Target Raised to $587

Canaccord Genuity has maintained a 'Buy' rating for Madrigal Pharmaceuticals (MDGL) and raised its price target from $578.00 to $587.00. Despite this optimism, the company's GF Score™ of 31/100, high Price-to-Sales ratio, and negative insider activity suggest potential overvaluation and financial challenges, particularly in …

Madrigal earnings in focus as Rezdiffra launch accelerates

Madrigal Pharmaceuticals is set to report its second-quarter earnings, with investors focused on the sustained momentum of its MASH drug, Rezdiffra. Analysts expect the company to narrow its loss significantly while increasing revenue, maintaining a strong buy consensus. The upcoming earnings will be a …

Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk

Madrigal Pharmaceuticals Inc (MDGL) has a risk assessment score of 7.08, ranking 17 out of 385 in the Biotechnology & Medical Research industry. The company's beta value is -1.06, indicating it tends to underperform during upward markets but experiences smaller declines in downward markets. …